Galanin Receptor Antagonist M35 but Not M40 or C7 Ameliorates Cerulein-Induced Acute Pancreatitis in Mice

Bhandari, Mayank; Kawamoto, Masahiko; Thomas, Anthony; Barreto, Savio George; Schloithe, Ann; Carati, Colin; Toouli, James; Saccone, G. T. P.

doi:10.1159/000314603

Cited by 7 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Galanin was reported to play a pro‐inflammatory role in cerulein‐induced acute murine pancreatitis. The disease was alleviated by galanin receptor antagonists and genetic deletion of galanin . Recent data indicate substantial involvement of GAL 3 in this model .…”

Section: Anti‐inflammatory Neuropeptidesmentioning

confidence: 76%

Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions

Pintér

Pozsgai

Hajna

et al. 2013

Brit J Clinical Pharma

View full text Add to dashboard Cite

Cross-talk between the nervous, endocrine and immune systems exists via regulator molecules, such as neuropeptides, hormones and cytokines. A number of neuropeptides have been implicated in the genesis of inflammation, such as tachykinins and calcitonin gene-related peptide. Development of their receptor antagonists could be a promising approach to anti-inflammatory pharmacotherapy. Anti-inflammatory neuropeptides, such as vasoactive intestinal peptide, pituitary adenylate cyclase-activating polypeptide, a-melanocyte-stimulating hormone, urocortin, adrenomedullin, somatostatin, cortistatin, ghrelin, galanin and opioid peptides, are also released and act on their own receptors on the neurons as well as on different inflammatory and immune cells. The aim of the present review is to summarize the most prominent data of preclinical animal studies concerning the main pharmacological effects of ligands acting on the neuropeptide receptors. Promising therapeutic impacts of these compounds as potential candidates for the development of novel types of anti-inflammatory drugs are also discussed.

show abstract

Section: Anti‐inflammatory Neuropeptidesmentioning

confidence: 76%

Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions

Pintér

Pozsgai

Hajna

et al. 2013

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…However, the receptor of alarin is still unknown (Sipkova et al 2017 ). Previous study showed that Ala6-25 Cys is an antagonist of alarin (Wang et al 2020 ), and C7 and M35 are the antagonists of galanin receptors (Zhang et al 2019 ; Bhandari et al 2010 ). We present found that Ala6-25 Cys, but not M35 or C7 reversed the attenuating effects of alarin on MI-induced cardiac fibrosis.…”

Section: Discussionmentioning

confidence: 99%

Alarin alleviated cardiac fibrosis via attenuating oxidative stress in heart failure rats

Ding

et al. 2021

Amino Acids

View full text Add to dashboard Cite

The present study was to explore whether alarin could alleviate heart failure (HF) and attenuate cardia fibrosis via inhibiting oxidative stress. The fibrosis of cardiac fibroblasts (CFs) was induced by angiotensin (Ang) II. HF models were induced by ligation of the left anterior descending artery to cause ischemia myocardial infarction (MI) in Sprague–Dawley rats. Alarin (1.0 nM/kg/d) was administrated by intraperitoneal injection for 28 days. The decreases of left ventricular (LV) ejection fraction (EF), fractional shortening (FS), the maximum of the first differentiation of LV pressure (LV ± dp/dtmax) and LV systolic pressure (LVSP), and the increases of LV volume in systole (LVVS), LV volume in diastole (LVVD), LV end-systolic diameter (LVESD) and LV end-diastolic diameter (LVEDD) in MI rats were improved by alarin treatment. The increases in the expression levels of collagen I, collagen III, and transforming growth factor (TGF)-β were inhibited by alarin treatment in CFs and in the hearts of MI rats. The levels of NADPH oxidase (Nox) activity, superoxide anions and malondialdehyde (MDA) levels were increased, and the level of superoxide dismutase (SOD) activity was reduced in Ang II-treated CFs, which were reversed by alarin. Nox1 overexpression reversed the effects of alarin on attenuating the increases of collagen I, collagen III and TGF-β expression levels induced by Ang II in CFs. These results indicated that alarin improved HF and cardiac fibrosis via inhibiting oxidative stress in HF rats. Nox1 played important roles in the regulation of alarin effects on attenuating CFs fibrosis induced by Ang II.

show abstract

“…It is also supported by another study that demonstrates that the alarin antagonist (the so-called Ala6-25Cys), but not the GalR blockers (M35 or C7), reverses the attenuating effects of alarin on myocardial infarction (MI)-induced cardiac fibrosis. Furthermore, this truncated alarin peptide (Ala6-25Cys) that missed the first five amino acids of the full-length alarin restores the inhibitory effects of alarin on angiotensin II-induced cardiac fibrosis (24,(122)(123)(124). Ala6-25Cys also antagonizes the acute orexigenic effects of centrally administered alarin (13,19).…”

Section: Arguments On Alarin Receptormentioning

confidence: 99%

Regulatory effects and potential therapeutic implications of alarin in depression, and arguments on its receptor

Abebe

Mengstie²,

Seid³

et al. 2022

Front. Psychiatry

View full text Add to dashboard Cite

Alarin is a pleiotropic peptide involved in a multitude of putative biological activities, notably, it has a regulatory effect on depression-like behaviors. Although further elucidating research is needed, animal-based cumulative evidence has shown the antidepressant-like effects of alarin. In light of its regulatory role in depression, alarin could be used as a promising antidepressant in future treatment for depression. Nevertheless, the available information is still insufficient and the therapeutic relevance of alarin in depression is still of concern. Moreover, a plethora of studies have reported that the actions of alarin, including antidepressant activities, are mediated by a separate yet unidentified receptor, highlighting the need for more extensive research. This review focuses on the current understanding of the regulatory effects and future therapeutic relevance of alarin on depression, and the arguments on its receptors.

show abstract

Galanin Receptor Antagonist M35 but Not M40 or C7 Ameliorates Cerulein-Induced Acute Pancreatitis in Mice

Cited by 7 publications

References 33 publications

Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions

Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions

Alarin alleviated cardiac fibrosis via attenuating oxidative stress in heart failure rats

Regulatory effects and potential therapeutic implications of alarin in depression, and arguments on its receptor

Contact Info

Product

Resources

About